Gonçalves M A, Pau M G, de Vries A A, Valerio D
Gene Therapy Section, Department of Molecular Cell Biology, Leiden University Medical Center, Wassenaarseweg 72, 2333 AL Leiden, The Netherlands.
Virology. 2001 Sep 30;288(2):236-46. doi: 10.1006/viro.2001.1073.
Gene therapy aims to complement or, ideally, correct defective genes. The broad clinical application of this emerging technology requires the development of safe high-capacity gene delivery vehicles that combine efficient transduction of dividing as well as quiescent cells with sustained transgene expression. Here we present a new hybrid vector system that unites favorable attributes of adenoassociated virus (AAV) and adenovirus (Ad) vectors in a single particle. This was achieved by inclusion of Ad packaging elements in different sized recombinant AAV genomes. In the presence of AAV replicative functions and a recombinant helper Ad, AAV/Ad hybrid particles were generated via encapsidation of AAV-dependent replicative intermediates into Ad capsids. In stringent in vitro models based on transduction of proliferating cells we show that AAV/Ad hybrid vectors are superior to Ad vectors in establishing prolonged transgene expression and can be used to deliver DNA fragments of at least 27 kb.
基因治疗旨在补充,理想情况下是纠正缺陷基因。这项新兴技术的广泛临床应用需要开发安全的高容量基因递送载体,该载体要将分裂细胞和静止细胞的高效转导与持续的转基因表达结合起来。在此,我们展示了一种新的混合载体系统,该系统在单个颗粒中结合了腺相关病毒(AAV)和腺病毒(Ad)载体的有利特性。这是通过在不同大小的重组AAV基因组中包含Ad包装元件来实现的。在AAV复制功能和重组辅助Ad存在的情况下,通过将AAV依赖性复制中间体包装到Ad衣壳中产生AAV/Ad混合颗粒。在基于增殖细胞转导的严格体外模型中,我们表明AAV/Ad混合载体在建立延长的转基因表达方面优于Ad载体,并且可用于递送至少27 kb的DNA片段。